B. Riley analyst Mayank Mamtani raised the firm’s price target on Journey Medical (DERM) to $12 from $9 and keeps a Buy rating on the shares following a transfer of coverage. The firm expects increased visibility into Emrosi’s early launch performance with the Q2 results in mid-August.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: